{"id":390595,"date":"2018-08-30T00:00:00","date_gmt":"2018-08-30T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0002-2018-biopharma-malignant-melanoma-current-treatment-physician-insights-eu5-2018\/"},"modified":"2026-04-30T11:25:20","modified_gmt":"2026-04-30T11:25:20","slug":"cutron0002-2018-biopharma-malignant-melanoma-current-treatment-physician-insights-eu5-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0002-2018-biopharma-malignant-melanoma-current-treatment-physician-insights-eu5-2018\/","title":{"rendered":"Malignant Melanoma | Current Treatment: Physician Insights | EU5 | 2018"},"content":{"rendered":"<p>Stage of disease, resectability of the primary tumor, and <em>BRAF-<\/em>mutation status (in the unresectable or metastatic setting) are key parameters that influence the treatment paradigm of malignant melanoma. Combination regimens including Bristol-Myers Squibb\u2019s Opdivo plus Yervoy, Novartis\u2019s Tafinlar plus Mekinist, and Roche\u2019s\u00a0Zelboraf plus Cotellic are an integral part of the treatment algorithm for unresectable or metastatic disease. This content explores surveyed medical oncologists\u2019 current treatment practices and the key factors that shape their prescribing choices.<\/p>\n<p><strong>Questions Answered<\/strong><\/p>\n<ul>\n<li>What is the uptake of immune checkpoint inhibitors and BRAF\/MEK inhibitors for treatment of <em>BRAF<\/em>-mutation-positive patients, according to surveyed medical oncologists?<\/li>\n<li>How do treatment practices for <em>BRAF<\/em> wild-type unresectable or metastatic malignant melanoma vary across the five European markets covered?<\/li>\n<li>What are the drivers and constraints that influence treatment decisions in the unresectable or metastatic setting for select targeted therapies?<\/li>\n<li>How do drug-treatment rates vary across key malignant melanoma patient populations, according to stage of disease and line of therapy?<\/li>\n<\/ul>\n<p><strong>Product Description<\/strong><\/p>\n<p><em>Current Treatment: Physician Insights<\/em> provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so you can create specific messaging around these treatment dynamics in order to more effectively increase or defend your market position.<\/p>\n<p><strong>Markets covered:<\/strong> France, Germany, Italy, Spain, United Kingdom.<\/p>\n<p><strong>Primary research: <\/strong> Survey of approximately 50\u00a0medical oncologists in\u00a0each EU5 country fielded in May 2018.<\/p>\n<p><strong>Key drugs covered:\u00a0<\/strong> Yervoy, Opdivo, Keytruda, Zelboraf, Tafinlar, Mekinist, Cotellic, Imlygic.<\/p>\n","protected":false},"template":"","class_list":["post-390595","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-malignant-melanoma","biopharma-product-current-treatment","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390595","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390595\/revisions"}],"predecessor-version":[{"id":393719,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390595\/revisions\/393719"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390595"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}